Aetna has added 250,000 Medicare Advantage members in the first quarter of 2018 on its way to a profitable first quarter as it looks to close a deal with CVS Health.
Suki, a startup that makes an AI-powered and voice-enabled digital assistant for doctors, has just landed $20 million in a funding round led by Venrock, with participation from First Round, Social Capital, and Marc Benioff.
Fitbit announced yesterday that it plans to utilize Google’s new Cloud Healthcare API, in order to continue its push into the world of serious healthcare devices. It’s a bit of a no-brainer as far as partnerships go.
After a strong 2017, Sanofi Pasteur got off to a less-than-stellar start this year. In China, inspectors put a temporary kibosh on imports of the pediatric shot Pentaxim, thanks to vaccine batches that failed to pass inspection. That move hobbled the shot's sales—and dragged the rest of the unit down, too.
GSK’s Cervarix and Merck’s previous version of Gardasil took about 10 years to reach the Chinese market. (Merck)
First Filing Acceptance for an Anti-PD-1 Therapy in Cervical Cancer
Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases.
To be clear, this doesn't mean you are likely to experience these side effects after going on birth control. But if you do notice any of them after you start, there could be a connection there, and it's worth talking to your doctor if you don't like the effects you're experiencing or notice anything out of the ordinary. Here are a few possible side effects of hormonal birth control that you may not have been told about.
Researchers from the University of Wisconsin-Madison have detailed a wearable device that can better measure muscle-tendon tension during certain activities, such as walking or running.
Researchers from the Saint Louis University School of Medicine have discovered why many multiple myeloma patients experience severe pain when treated with the anticancer drug bortezomib. The study, which will be published April 27 in the Journal of Experimental Medicine, suggests that a drug already approved to treat multiple sclerosis could mitigate this effect, allowing myeloma patients to successfully complete their treatment and relieving the pain of myeloma survivors.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.